The pharmacological consequences of the binding of anti-rheumatic drugs to plasma proteins in the treatment of rheumatoid arthritis
- PMID: 382804
- DOI: 10.1007/BF02024737
The pharmacological consequences of the binding of anti-rheumatic drugs to plasma proteins in the treatment of rheumatoid arthritis
Abstract
Evidence is presented that rheumatoid arthritis is a disease resulting from abnormal protein binding and that anti-rheumatic drugs act by correcting the abnormal binding.
Similar articles
-
Protein binding of some non-steroidal anti-inflammatory drugs in rheumatoid arthritis.Clin Pharmacokinet. 1982 Jan-Feb;7(1):85-92. doi: 10.2165/00003088-198207010-00005. Clin Pharmacokinet. 1982. PMID: 7075085
-
The displacement of L-tryptophan and dipeptides from bovine albumin in vitro and from human plasma in vivo by antirheumatic drugs.J Pharm Pharmacol. 1971 Jun;23(6):393-8. doi: 10.1111/j.2042-7158.1971.tb08669.x. J Pharm Pharmacol. 1971. PMID: 4397176 No abstract available.
-
[Protein binding of salicylates in rheumatoid arthritis].Rev Rhum Mal Osteoartic. 1982 May;49(6):447-52. Rev Rhum Mal Osteoartic. 1982. PMID: 7112023 French.
-
A review of possible mechanisms of action of the antirheumatic drug, alclofenac.Curr Med Res Opin. 1975;3(5):249-63. doi: 10.1185/03007997509114775. Curr Med Res Opin. 1975. PMID: 241594 Review.
-
[Pharmacologic therapy of rheumatoid arthritis with delayed-action anti-rheumatic drugs].Internist (Berl). 1993 Jan;34(1):9-17. Internist (Berl). 1993. PMID: 8440581 Review. German. No abstract available.
Cited by
-
Characterization of salicylate binding to synovial fluid and plasma protein in patients with rheumatoid arthritis.Eur J Clin Pharmacol. 1980 Nov;18(5):403-6. doi: 10.1007/BF00636793. Eur J Clin Pharmacol. 1980. PMID: 7439262